Cargando…

Integrating Mechanisms in Thrombotic Peripheral Arterial Disease

Peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, is underdiagnosed in the general population. Despite the extensive research performed to unravel its pathophysiology, inadequate knowledge exists, thus preventing the development of new treatments. This review aims to hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagy, Magdolna, van der Meijden, Paola E. J., Glunz, Julia, Schurgers, Leon, Lutgens, Esther, ten Cate, Hugo, Heitmeier, Stefan, Spronk, Henri M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695058/ https://www.ncbi.nlm.nih.gov/pubmed/36422558 http://dx.doi.org/10.3390/ph15111428

Ejemplares similares

Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease
por: Kremers, B. M. M., et al.
Publicado: (2022)

The Composition and Physical Properties of Clots in COVID-19 Pathology
por: Dauwerse, Sierk, et al.
Publicado: (2022)

Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis
por: Kremers, Bram, et al.
Publicado: (2020)

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease
por: Baidildinova, Gaukhar, et al.
Publicado: (2021)

Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment
por: ten Cate, Hugo, et al.
Publicado: (2020)

Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice
por: Posthuma, Jelle J., et al.
Publicado: (2019)

What to expect from drug targeting factor XI?
por: Nagy, Magdolna, et al.
Publicado: (2022)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Evaluation of the analytical performance of the PC100 platelet counter
por: Nagy, Magdolna, et al.
Publicado: (2021)

Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case–Control Study
por: Kleinegris, Marie-Claire F., et al.
Publicado: (2017)

Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial
por: Willems, Loes H., et al.
Publicado: (2022)

Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease
por: Kremers, Bram M. M., et al.
Publicado: (2019)

Blood coagulation and the risk of atherothrombosis: a complex relationship
por: Spronk, Henri MH, et al.
Publicado: (2004)

Diabetes- versus smoking-related thrombo-inflammation in peripheral artery disease
por: Alnima, T., et al.
Publicado: (2023)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

The coagulation system in atherothrombosis: Implications for new therapeutic strategies
por: Olie, Renske H., et al.
Publicado: (2018)

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets
por: Panova-Noeva, Marina, et al.
Publicado: (2019)

Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
por: Kremers, B. M. M., et al.
Publicado: (2023)

Screen or not to screen for peripheral arterial disease: guidance from a decision model
por: Vaidya, Anil, et al.
Publicado: (2014)

Prevention and treatment of the post‐thrombotic syndrome
por: ten Cate‐Hoek, Arina J.
Publicado: (2018)

Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability
por: van de Berg, Tom W., et al.
Publicado: (2021)

Integrating platelet and coagulation activation in fibrin clot formation
por: Swieringa, Frauke, et al.
Publicado: (2018)

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies
por: Panova-Noeva, Marina, et al.
Publicado: (2020)

P1647: CHRONIC INFLAMMATORY DISEASES INCREASE THE RISK OF POST-THROMBOTIC SYNDROME: A PROSPECTIVE COHORT STUDY
por: Iding, Aaron F.J., et al.
Publicado: (2023)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
por: Willems, Loes H., et al.
Publicado: (2021)

Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System
por: Perrella, Gina, et al.
Publicado: (2021)

Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding
por: Veninga, Alicia, et al.
Publicado: (2020)

The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial
por: ten Cate-Hoek, Arina J, et al.
Publicado: (2014)

Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model
por: Grottke, Oliver, et al.
Publicado: (2013)

Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments
por: Petersohn, Svenja, et al.
Publicado: (2019)

Thrombin–Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis
por: Hulshof, Anne-Marije, et al.
Publicado: (2021)

Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis
por: Pallares Robles, Alejandro, et al.
Publicado: (2022)

Differential Fibrinolysis Profile in COVID-19 Patients Dependent on Immunosuppressive Treatment Regimen: A Nested Case-Control Study
por: Nagy, Magdolna, et al.
Publicado: (2022)

Biomarkers of sustained systemic inflammation and microvascular dysfunction associated with post-COVID-19 condition symptoms at 24 months after SARS-CoV-2-infection
por: Jacobs, Lotte M. C., et al.
Publicado: (2023)

PB2642: EVALUATION OF INNOVATIVE LABORATORY TESTS TO PREDICT A THROMBOTIC PHENOTYPE IN A FAMILY WITH DYSFIBRINOGENEMIA AND A NOVEL FGG MUTATION.
por: Monard, Amaury, et al.
Publicado: (2023)

Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model
por: Zentai, Christian, et al.
Publicado: (2015)

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019)

Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
por: Henskens, Yvonne M. C., et al.
Publicado: (2018)

Mean Platelet Volume and Arterial Stiffness – Clinical Relationship and Common Genetic Variability
por: Panova-Noeva, Marina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v573rsamhfoj25u09ir2jklvee